Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-26T18:22:17.208Z Has data issue: false hasContentIssue false
  • English
  • Français

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine

Published online by Cambridge University Press:  19 June 2009

Joanne Rodda ,
Shirlony Morgan  and
Zuzana Walker
Joanne Rodda*
Affiliation:
Department of Mental Health Sciences, University College London, London, U.K.
Shirlony Morgan
Affiliation:
Department of Mental Health Sciences, University College London, London, U.K.
Zuzana Walker
Affiliation:
Department of Mental Health Sciences, University College London, London, U.K.
*
Correspondence should be addressed to: Dr Joanne Rodda, Department of Mental Health Sciences, University College London, Windeyer Building, 46 Cleveland Street, W1T 4JF, U.K. Phone: +44 (0)1279 827893; Fax: +44 (0)1992 571089 Email: [email protected].
Get access

Abstract

Background: The study aim was to conduct a systematic review of the evidence from randomized, placebo controlled trials related to the efficacy of donepezil, rivastigmine and galantamine in the treatment of behavioral and psychological symptoms of Alzheimer's disease.

Methods: Electronic database searches of MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were carried out using multiple search terms. Articles included were original publications of randomized, placebo-controlled trials of monotherapy of donepezil, rivastigmine or galantamine that reported a behavioral outcome measure.

Results: 14 studies were identified that matched inclusion criteria. Nine were of donepezil, three of galantamine and two of rivastigmine. Median study treatment length was 24 weeks (range 12–170). Most studies used the Neuropsychiatric Inventory as a behavioral outcome measure although three used specific scales for either agitation or apathy. Four studies were specifically designed to assess behavioral outcomes whilst in the majority of studies behavioral outcomes were only secondary measures. Three studies found statistically significant, albeit modest, differences in the change of NPI total score between drug and placebo. The interpretation of the results of many studies is limited by methodological considerations, including generally low NPI scores at baseline and the investigation of behavioral and psychological symptoms of dementia (BPSD) as secondary outcomes.

Conclusions: The evidence base regarding the efficacy of cholinesterase inhibitors in BPSD is limited, in part due to methodological considerations. In the absence of alternative safe and effective management options, the use of cholinesterase inhibitors is an appropriate pharmacological strategy for the management of BPSD in Alzheimer's disease.

Keywords

Alzheimer'sBPSDbehavioralcholinesterase inhibitors
Type
Review Article
Information
International Psychogeriatrics , Volume 21 , Issue 5 , October 2009 , pp. 813 - 824
Copyright
Copyright © International Psychogeriatric Association 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ballard, C. et al. (2005). Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ, 330, 874.CrossRefGoogle ScholarPubMed
Ballard, C. and Waite, J. (2006). The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews, CD003476.CrossRefGoogle Scholar
Black, S. E. et al. (2007). Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology, 69, 459–469.CrossRefGoogle ScholarPubMed
Brodaty, H., Corey-Bloom, J., Potocnik, F. C., Truyen, L., Gold, M. and Damaraju, C. R. (2005). Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 20, 120–132.CrossRefGoogle ScholarPubMed
Coen, R. F., Swanwick, G. R., O'Boyle, C. A. and Coakley, D. (1997). Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. International Journal of Geriatric Psychiatry, 12, 331–336.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
Cohen-Mansfield, J. (1986). Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. Journal of the American Geriatrics Society, 34, 722–727.CrossRefGoogle ScholarPubMed
Cohen-Mansfield, J., Marx, M. S. and Rosenthal, A. S. (1989). A description of agitation in a nursing home. Journal of Gerontology, 44, M77–M84.CrossRefGoogle ScholarPubMed
Committee on Safety of Medicines (2004). Atypical Antipsychotic Drugs and Stroke. Available at: http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON1004298.Google Scholar
Courtney, C. et al. (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet, 363, 2105–2115.Google ScholarPubMed
Cummings, J. L. (1997). The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology, 48, S10–S16.CrossRefGoogle ScholarPubMed
Cummings, J. L. and Back, C. (1998). The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. American Journal of Geriatric Psychiatry, 6, S64–S78.CrossRefGoogle ScholarPubMed
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314.CrossRefGoogle ScholarPubMed
FDA Public Health Advisory Centre for Drug Evaluation and Research (2005). Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at: www.fda.gov/Cder/drug/advisory/antipsychotics.htm.Google Scholar
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P. and Whalen, E. (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57, 613–620.CrossRefGoogle ScholarPubMed
Gauthier, S. et al. (2002). Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics, 14, 389–404.Google ScholarPubMed
Gauthier, S., Loft, H. and Cummings, J. (2008). Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. International Journal of Geriatric Psychiatry, 23, 537–545.CrossRefGoogle ScholarPubMed
Gill, S. S. et al. (2007). Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine, 146, 775–786.CrossRefGoogle ScholarPubMed
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A. and Busto, U. E. (2005). Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ, 331, 1169.CrossRefGoogle ScholarPubMed
Holmes, C. et al. (2004). The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology, 63, 214–219.CrossRefGoogle ScholarPubMed
Howard, R. J. et al. (2007). Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357, 1382–1392.CrossRefGoogle ScholarPubMed
Jost, B. C. and Grossberg, G. T. (1996). The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. Journal of the American Geriatrics Society, 44, 1078–1081.CrossRefGoogle ScholarPubMed
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H. P. and Van Den, B. H. (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ, 331, 321–327.CrossRefGoogle ScholarPubMed
Kaufer, D. I., Cummings, J. L. and Christine, D. (1996). Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. Journal of Geriatric Psychiatry and Neurology, 9, 1–6.CrossRefGoogle ScholarPubMed
Lanctôt, K. L., Herrmann, N., Van, R. R., Eryavec, G. and Naranjo, C. A. (2002). Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry, 17, 531–541.CrossRefGoogle ScholarPubMed
Livingston, G., Johnston, K., Katona, C., Paton, J. and Lyketsos, C. G. (2005). Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. American Journal of Psychiatry, 162, 1996–2021.CrossRefGoogle Scholar
Lonergan, E. T., Cameron, M. and Luxenberg, J. (2004). Valproic acid for agitation in dementia. Cochrane Database of Systematic Reviews, CD003945.CrossRefGoogle Scholar
Maelicke, A. (2000). Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 11 (Suppl. 1), 11–18.CrossRefGoogle ScholarPubMed
Martinon-Torres, G., Fioravanti, M. and Grimley, E. J. (2004). Trazodone for agitation in dementia. Cochrane Database of Systematic Reviews, CD004990.CrossRefGoogle Scholar
Meehan, K. M. et al. (2002). Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology, 26, 494–504.CrossRefGoogle ScholarPubMed
Mega, M. S., Cummings, J. L., Fiorello, T. and Gornbein, J. (1996). The spectrum of behavioral changes in Alzheimer's disease. Neurology, 46, 130–135.CrossRefGoogle ScholarPubMed
Minger, S. L. et al. (2000). Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology, 55, 1460–1467.CrossRefGoogle ScholarPubMed
National Institute for Health and Clinical Excellence/Social Care Institute for Excellence (2006). Dementia: Supporting People with Dementia and their Carers in Health and Social Care. NICE Clinical Guidance 42. London: National Institute for Health and Clinical Excellence. Available at: www.nice.org.uk/cG042.Google Scholar
Nyth, A. L. and Gottfries, C. G. (1990). The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. British Journal of Psychiatry, 157, 894–901.CrossRefGoogle ScholarPubMed
Olin, J. T., Fox, L. S., Pawluczyk, S., Taggart, N. A. and Schneider, L. S. (2001). A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. American Journal of Geriatric Psychiatry, 9, 400–405.CrossRefGoogle ScholarPubMed
Pollock, B. G. et al. (2002). Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. American Journal of Psychiatry, 159, 460–465.CrossRefGoogle ScholarPubMed
Rockwood, K., Mintzer, J., Truyen, L., Wessel, T. and Wilkinson, D. (2001). Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 71, 589–595.CrossRefGoogle ScholarPubMed
Rovner, B. W., Kafonek, S., Filipp, L., Lucas, M. J. and Folstein, M. F. (1986). Prevalence of mental illness in a community nursing home. American Journal of Psychiatry, 143, 1446–1449.Google Scholar
Schneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C. and Wang, P. S. (2007). Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal, 176, 627–632.CrossRefGoogle ScholarPubMed
Schneider, L. S., Dagerman, K. and Insel, P. S. (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry, 14, 191–210.CrossRefGoogle ScholarPubMed
Seltzer, B. et al. (2004). Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Archives of Neurolology, 61, 1852–1856.CrossRefGoogle ScholarPubMed
Starkstein, S. E., Mayberg, H. S., Preziosi, T. J., Andrezejewski, P., Leiguarda, R. and Robinson, R. G. (1992). Reliability, validity, and clinical correlates of apathy in Parkinson's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 4, 134–139.Google ScholarPubMed
Starkstein, S. E., Petracca, G., Chemerinski, E. and Kremer, J. (2001). Syndromic validity of apathy in Alzheimer's disease. American Journal of Psychiatry, 158, 872–877.CrossRefGoogle ScholarPubMed
Steele, C., Rovner, B., Chase, G. A. and Folstein, M. (1990). Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. American Journal of Psychiatry, 147, 1049–1051.Google ScholarPubMed
Tariot, P. N., Podgorski, C. A., Blazina, L. and Leibovici, A. (1993). Mental disorders in the nursing home: another perspective. American Journal of Psychiatry, 150, 1063–1069.Google ScholarPubMed
Tariot, P. N. et al. (1998). Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. American Journal of Psychiatry, 155, 54–61.CrossRefGoogle ScholarPubMed
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S. and Ding, C. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 54, 2269–2276.CrossRefGoogle ScholarPubMed
Tariot, P. N. et al. (2001). A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society, 49, 1590–1599.Google ScholarPubMed
U.S. Food and Drug Administration Centre for Drug Evaluation and Research (2008). Information for Healthcare Professionals: Antipsychotics. Available at: www.fda.gov/cder/drug/infosheets/HCP/antipsychotics_conventional.htm.Google Scholar
Winblad, B. et al. (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology, 57, 489–495.CrossRefGoogle ScholarPubMed
Winblad, B. et al. (2006). Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet, 367, 1057–1065.CrossRefGoogle ScholarPubMed
Winblad, B. et al. (2007). IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology, 69, S14–S22.CrossRefGoogle ScholarPubMed
Wood, S. et al. (2000). The use of the neuropsychiatric inventory in nursing home residents: characterization and measurement. American Journal of Geriatric Psychiatry, 8, 75–83.CrossRefGoogle ScholarPubMed